Boehringer Ingelheim Targets KRAS Mutations with Lupin’s LNP3794

By Pratika Pahwa & Michelle Liu

Pharma Deals Review: Vol 2019 Issue 10 (Table of Contents)

Published: 21 Oct-2019

DOI: 10.3833/pdr.v2019.i10.2462     ISSN: 1756-7874

Section: Licensing



Continuing to expand its footprint in the oncogenic KRAS mutations space, Boehringer Ingelheim has entered into a licensing, development and commercialisation agreement with Lupin for LNP3794, a mitogen-activated protein kinase inhibitor...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details